Kalpit Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kalpit Shah has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Matthew J. Wongchenko
Department of Translational Medicine—Oncology, Genentech, South San Francisco, CA
50 shared publications - Chang Xu
Foundation Medicine, Inc., Boston, MA, USA
35 shared publications - Christopher J. Sweeney
South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia
35 shared publications - David Fabrizio
Foundation Medicine Inc, Boston, Massachusetts, USA
35 shared publications - Jie He
Affiliation Foundation Medicine, Inc., Boston, Massachusetts, United States of America
35 shared publications - Kobe Yuen
Genentech, South San Francisco, California
35 shared publications
Latest Publications
- 22 September 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Transcriptomic Plasticity and Its Spatial Architecture Shape Melanoma Response to Immunotherapy and Its Combination With BRAF/MEKi
PURPOSE: In BRAF -mutant melanoma, clinical trials evaluating combination and sequencing strategies of MAPK-targeted therapy with immune checkpoint blockade (ICB) have yielded mixed results. We sought to define tumor biology associated with resistance to ICB and response to ICB and its combination with MAPK-targeted therapy, and determine biomarkers to guide treatment strategies. PATIENTS AND METHODS: We integrated clinical with multi-omics data from IMspire150, BRIM, AVAST-M, and publicly available immunotherapy-treated melanoma cohorts to identify transcriptional states associated with response or resistance to ICB and BRAF/MEK inhibition combined with ICB. Functional assays and spatial transcriptomic analyses were used to evaluate and validate the underlying mechanistic hypothesis associated with response or resistance to BRAF/MEK inhibition combined with ICB. RESULTS: Two major ICB-resistant states were identified: differentiated and undifferentiated tumors with distinct clinical and microenvironmental features. Differentiated tumors were associated with improved outcomes with BRAF/MEK inhibition combined with ICB, despite limited benefit from ICB alone. In contrast, undifferentiated tumors were less responsive to both ICB and MAPK-targeted combinations and were enriched for angiogenic and stromal programs. These tumors were associated with improved outcomes following anti-vascular endothelial growth factor therapy in retrospective analyses and showed sensitivity to CDK7 inhibition in preclinical models. CONCLUSION: Using the largest melanoma clinical-molecular data set, we have defined a transcriptional classification framework that defines biologically distinct patient subgroups associated with response or resistance to ICB and its combination with MAPK-targeted therapies. These findings support biomarker-driven approaches to identify patients who may benefit from therapeutic escalation by adding MAPK inhibition to ICB rather than ICB alone, as well as a subgroup with persistent unmet need.
- 22 September 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Transcriptomic Plasticity and Its Spatial Architecture Shape Melanoma Response to Immunotherapy and Its Combination With BRAF/MEKi
PURPOSE: In BRAF -mutant melanoma, clinical trials evaluating combination and sequencing strategies of MAPK-targeted therapy with immune checkpoint blockade (ICB) have yielded mixed results. We sought to define tumor biology associated with resistance to ICB and response to ICB and its combination with MAPK-targeted therapy, and determine biomarkers to guide treatment strategies. PATIENTS AND METHODS: We integrated clinical with multi-omics data from IMspire150, BRIM, AVAST-M, and publicly available immunotherapy-treated melanoma cohorts to identify transcriptional states associated with response or resistance to ICB and BRAF/MEK inhibition combined with ICB. Functional assays and spatial transcriptomic analyses were used to evaluate and validate the underlying mechanistic hypothesis associated with response or resistance to BRAF/MEK inhibition combined with ICB. RESULTS: Two major ICB-resistant states were identified: differentiated and undifferentiated tumors with distinct clinical and microenvironmental features. Differentiated tumors were associated with improved outcomes with BRAF/MEK inhibition combined with ICB, despite limited benefit from ICB alone. In contrast, undifferentiated tumors were less responsive to both ICB and MAPK-targeted combinations and were enriched for angiogenic and stromal programs. These tumors were associated with improved outcomes following anti-vascular endothelial growth factor therapy in retrospective analyses and showed sensitivity to CDK7 inhibition in preclinical models. CONCLUSION: Using the largest melanoma clinical-molecular data set, we have defined a transcriptional classification framework that defines biologically distinct patient subgroups associated with response or resistance to ICB and its combination with MAPK-targeted therapies. These findings support biomarker-driven approaches to identify patients who may benefit from therapeutic escalation by adding MAPK inhibition to ICB rather than ICB alone, as well as a subgroup with persistent unmet need.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Supplementary Figure 3. Evolution of PI3K-AKT and AR pathway.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Supplementary Figure 3. Evolution of PI3K-AKT and AR pathway.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Supplementary Table 1. This table contains the genes comprising the pathway gene signature used to evaluate genetic alterations in prostate cancer specimens.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Supplementary Table 1. This table contains the genes comprising the pathway gene signature used to evaluate genetic alterations in prostate cancer specimens.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Data from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Purpose:Many preclinical hypotheses, including reciprocal feedback activation between the androgen receptor (AR)–PI3K pathway in PTEN loss and AR signaling inhibitor–induced “BRCAness” regardless of BRCA1/2 status, have struggled to translate into clinical benefit for patients with metastatic prostate cancer. This gap in translatability, particularly in metastatic castration-resistant prostate cancer (mCRPC), may stem from a limited understanding of prostate cancer evolution. A key challenge is the correlation between early-stage tumor genetics and mCRPC. By examining clinical, genomic, and molecular changes over time, we aimed to refine clinical trial design.Experimental Design:Using a comprehensive dataset from electronic health records with genomic profiling, a shift in the prognostic value of biomarkers from metastatic hormone-sensitive prostate cancer (mHSPC) to mCRPC was observed. Additionally, genomic and transcriptomic analyses of primary tumors from the IPATential150 trial and mCRPC samples from the Stand Up To Cancer cohort examined the changing AR–PI3K signaling correlation.Results:PI3K–AKT pathway alterations lost their prognostic significance in later stages. Although AR and PI3K–AKT signaling were inversely correlated in primary tumors, this relationship was disrupted in mCRPC, independent of PIK3CA/AKT1/PTEN status. We identified broad transcriptional rewiring associated with AR signaling, increasing tumor heterogeneity. Improving the understanding of early-stage disease, we identified a high-risk mHSPC subset enriched for AR alterations. Additionally, in a subset of patients, AR ligand-binding domain mutations preceded amplification, potentially leading to preferential amplification of the mutant AR form.Conclusions:Our findings underscore the dynamic nature of prostate tumor biology and emphasize the need for translational research to validate preclinical hypotheses in clinically relevant settings, ultimately improving trial design and therapeutic strategies.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Purpose:Many preclinical hypotheses, including reciprocal feedback activation between the androgen receptor (AR)–PI3K pathway in PTEN loss and AR signaling inhibitor–induced “BRCAness” regardless of BRCA1/2 status, have struggled to translate into clinical benefit for patients with metastatic prostate cancer. This gap in translatability, particularly in metastatic castration-resistant prostate cancer (mCRPC), may stem from a limited understanding of prostate cancer evolution. A key challenge is the correlation between early-stage tumor genetics and mCRPC. By examining clinical, genomic, and molecular changes over time, we aimed to refine clinical trial design.Experimental Design:Using a comprehensive dataset from electronic health records with genomic profiling, a shift in the prognostic value of biomarkers from metastatic hormone-sensitive prostate cancer (mHSPC) to mCRPC was observed. Additionally, genomic and transcriptomic analyses of primary tumors from the IPATential150 trial and mCRPC samples from the Stand Up To Cancer cohort examined the changing AR–PI3K signaling correlation.Results:PI3K–AKT pathway alterations lost their prognostic significance in later stages. Although AR and PI3K–AKT signaling were inversely correlated in primary tumors, this relationship was disrupted in mCRPC, independent of PIK3CA/AKT1/PTEN status. We identified broad transcriptional rewiring associated with AR signaling, increasing tumor heterogeneity. Improving the understanding of early-stage disease, we identified a high-risk mHSPC subset enriched for AR alterations. Additionally, in a subset of patients, AR ligand-binding domain mutations preceded amplification, potentially leading to preferential amplification of the mutant AR form.Conclusions:Our findings underscore the dynamic nature of prostate tumor biology and emphasize the need for translational research to validate preclinical hypotheses in clinically relevant settings, ultimately improving trial design and therapeutic strategies.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Supplementary Figure 4. Investigation of reciprocal feedback regulation between AR and PI3K-AKT signaling in in vitro cell lines using AR inhibitors and AR degrader.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Supplementary Figure 4. Investigation of reciprocal feedback regulation between AR and PI3K-AKT signaling in in vitro cell lines using AR inhibitors and AR degrader.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Supplementary Table 8. This table summarizes the results of PI3K-AKT pathway signature analysis across multiple single-cell datasets (both published and unpublished). The table reports median and mean Z-scores from GSEA (Gene Set Enrichment Analysis), highlighting pathway enrichment across different cell types within each dataset.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Supplementary Table 8. This table summarizes the results of PI3K-AKT pathway signature analysis across multiple single-cell datasets (both published and unpublished). The table reports median and mean Z-scores from GSEA (Gene Set Enrichment Analysis), highlighting pathway enrichment across different cell types within each dataset.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Supplementary Figure 2. Exploration of PI3K-AKT genetic pathway alteration and gene signature in clinical and published single cell dataset.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Supplementary Figure 2. Exploration of PI3K-AKT genetic pathway alteration and gene signature in clinical and published single cell dataset.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Supplementary Table 4. This table summarizes key demographic and geographic considerations for the prostate cancer cohort studied.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Supplementary Table 4. This table summarizes key demographic and geographic considerations for the prostate cancer cohort studied.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Supplementary Figure 1. Exploration of mHSPC and mCRPC cohort.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Supplementary Figure 1. Exploration of mHSPC and mCRPC cohort.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Supplementary Table 2. Following analysis details protein coding genes and their pearsons correlation with PTEN IHC amongst prostate tumor tissue collected from patients enrolled in the IPATential150 trial.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Supplementary Table 2. Following analysis details protein coding genes and their pearsons correlation with PTEN IHC amongst prostate tumor tissue collected from patients enrolled in the IPATential150 trial.